echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAHA: Analysis of the efficacy of intransigent in patients with normal blood test scores associated with persistent hypertension

    JAHA: Analysis of the efficacy of intransigent in patients with normal blood test scores associated with persistent hypertension

    • Last Update: 2020-12-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Persistent hypertension may be a sodium retention state caused by abnormal aldehyde ketone secretion.
    recently, a study published in JAHA, an authoritative journal in the field of cardiovascular disease, was a secondary analysis of the trial of aldosterone antagonists for the treatment of normal heart function heart failure (TOPCAT), which included patients with normal blood failure (HFpEF) with (n-1004) and non-persistent hypertension (n-2437).
    Transcal hypertension is defined as hypertension in patients with systolic blood pressure ≥130mmHg and/or diastolic pressure ≥80mmHg) despite the simultaneous use of renin-angiotensin system blockers (angiotensin conversion enzyme inhibitors/angiotensin blockers) calcium channel blockers and diuretics≥
    the study was a complex outcome of cardiovascular death, cardiac arrest or hospitalization for heart failure.
    researchers analyzed the risk ratio (HRs) of 95% CI in the in-screw ester group using the Cox proportional risk model and compared it to the placebo group.
    the risk of major outcome events in patients with persistent hypertension associated with intransigent hypertension was significantly lower than in the placebo group (HR 0.70; 95% CI was 0.53-0.91; P=0.009), while in patients with HFpEF without persistent hypertension, there was no significant difference between the two groups of major outcome event risk (HR was 1.00); 95% CI is 0.83-1.20;
    there is a significant interaction between the use of intra-screw esters and stubborn hypertension (P-0.03).
    , it can be seen that intrasterester may be an effective drug for treating HFpEF patients with persistent hypertension.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.